I-SyncoZymes

iindaba

Inkqubela yophando malunga nokuhlanganiswa kwe-enzyme yezinto ezinokubangela i-Clenbuterol ngentsebenziswano phakathi kweYunivesithi yaseNorway yeSayensi neTekhnoloji kunye neShangke Biomedical

I-Clenbuterol, yi-agonist ye-β2-adrenergic (β2-adrenergic agonist), efana ne-ephedrine (Ephedrine), isetyenziswa rhoqo eklinikhi ukunyanga isifo esingapheliyo sokuvaleka kwemiphunga (COPD). Ikwasetyenziswa njenge-bronchodilator ukunciphisa ukuqaqanjelwa yi-asthma. Kwiminyaka yoo-1980, inkampani yaseMelika iCyanamid yafumanisa ngempazamo ukuba inemiphumo ecacileyo yokukhuthaza ukukhula, ukuphucula izinga lenyama engenamafutha kunye nokunciphisa amafutha, ngoko ke yasetyenziswa njenge-clenbuterol ekukhuliseni izilwanyana. Nangona kunjalo, ngenxa yemiphumo yayo emibi, i-European Community yathintela ukusetyenziswa kwe-clenbuterol njengesongezelelo sokondla ukususela nge-1 kaJanuwari 1988. Yavalwa yi-FDA ngo-1991. Ngo-1997, uMphathiswa wezoLimo weRiphabliki yabantu baseTshayina wathintela ngokungqongqo ukusetyenziswa kweehomoni ze-beta-adrenergic ekuveliseni ukutya kunye nokukhulisa izilwanyana, kwaye i-Clenbuterol hydrochloride yabekwa kwindawo yokuqala.

Nangona kunjalo, i-Clenbuterol ye-racemic ibonakalisiwe kutshanje ukuba iyanciphisa umngcipheko wesifo sikaParkinson. Ukuqinisekisa ukuba zeziphi (okanye zombini) ii-isomers ezivelisa esi siphumo, i-enantiomer ye-Clenbuterol ecocekileyo kufuneka ifundwe ngokwahlukeneyo.

Kwinqaku lakutshanje, iqela lophando lika-Elisabeth Egholm Jacobsen weSebe leKhemistri, kwiYunivesithi yeSayensi neTekhnoloji yaseNorway, ngokubambisana noGqr. Zhu Wei waseShangke Bio, bakhuthaze ukwenziwa kwe-ketoreductase KRED kunye ne-cofactor nicotinamide adenine dinucleoside phosphate (NADPH). (R)-1-(4-Amino-3,5-dichlorophenyl)-2-bromoethan-1-ol, ee > 93%; kunye ne-(S)-N-(2 yenziwe yinkqubo efanayo ,6-Dichloro-4-(1-hydroxyethyl)phenyl)acetamide, ee >98%. Zombini ezi zinto ziphakathi zingabaphambili be-clenbuterol isomers. I-ketoreductase ES-KRED-228 esetyenziswe kolu phononongo yayivela kwiShangke Biopharmaceutical (Shanghai) Co., Ltd. Iziphumo zophando "I-Chemoenzymatic Synthesis of Synthons as Precursors for Enantiopure Clenbuterol and Other -2-Agonists" zapapashwa kwi-"Catalysts" ngoNovemba 4, 2018.

Inkqubela phambili yophando malunga nokuhlanganiswa kwee-enzyme

Ixesha lokuthumela: Agasti-26-2022